Chava Kinkis-Sadary
FDA investigator
Appears on 1 document from 2024, mostly at sites in Israel. Most often cites general requirements (21 CFR 211.160).
- 1
- Documents on file
- 12.0
- Observations per 483
- 2024
- First seen
- 2024
- Most recent
What they cite most
From 12 observations- 21 CFR 211.160General requirements2
- 21 CFR 211.42Design and construction features2
- 21 CFR 211.67Equipment cleaning and maintenance2
- 21 CFR 211.100Written procedures; deviations1
- 21 CFR 211.110Sampling and testing of in-process materials and drug products1
- 21 CFR 211.192Production record review1
Activity by year
2024: 1
Where
Israel 1
Often inspects with
Is Chava Kinkis-Sadary coming to your site?
Our team writes custom reports before an inspection: what this investigator cites most, how they write it up, and how your site's history compares, in one brief you can circulate.
Ask about any investigator in Claude or ChatGPT with the AI connector.
Inspection history
1 document, newest first| Date | Firm | Location | Observations | Open |
|---|---|---|---|---|
| 2024-02-24 | 483 OMRIX BIOPHARMACEUTICALS LTDFeb 24, 2024 · RAMAT GAN, Israel | RAMAT GAN, Israel | 12 |
About this profile
What does Chava Kinkis-Sadary inspect?
Chava Kinkis-Sadary appears on 1 document on file covering 1 site, mostly in Israel.
What do they cite most often?
21 CFR 211.160 (general requirements), followed by 21 CFR 211.42 and 21 CFR 211.67.
Can I read the observations?
Each document page previews the opening words of every observation. The full documents are available to buy, one at a time or together.
How current is this profile?
The most recent document on file for Chava Kinkis-Sadary is dated Feb 24, 2024.